CHF 40,000 for aquafarming using mycellium technology, regeneration through protein engineering, and a vital patient data stream
27.11.2023
KIDEMIS, Orio Therapeutics, and Rheo win Venture Kick's second stage of financial and entrepreneurial support. Their projects are set to disrupt aquafeed by providing economically viable, SDG-compliant, and nutritionally superior solutions for the industry; lower drug usage, costs, and side effects while improving therapeutic outcomes; and replace all manual vitals measurements in the hospital with a data stream from the patient upper arm sensors.
 |
 |
 KIDEMIS: CEO Constantin Marakhov, CSO-CTO Sean Wassermann, and Finance-Strategy Advisor John Erocsson
|
|
 Orio Therapeutics: CEO Ziad Julier and CSO Mikaël Martino
|
|
 rheo: CEO Philipp Vetter and CTO Jonathan Fisher
|
|
KIDEMIS: Growing a Sustainable Future for Aquafarming Using Mycelium Technology
Aquaculture (farmed seafood) is growing at substantial rates mainly due to ocean depletion and changes from meat to a more healthy diet, however, aquafeed supply is under pressure and is in search of sustainable solutions. On the other hand, there is a problem of proper utilization of agricultural sidestreams, which currently are accumulating in huge quantities or ending up in landfills. With KIDEMIS proprietary fermentation technology low-value sidestreams are converted to low-cost, sustainable & high-quality nutrition solutions, which could be used in either feed or food. In particular, KIDEMIS mycoprotein is set to disrupt aquafeed by providing economically viable, SDG-compliant, and nutritionally superior solutions for the industry.
The company was established in 2023. Founders and Board Members include CEO Dr Constantin Marakhov, CSO/CTO Sean Wassermann, and John Ericsson responsible for Finance/Strategy. KIDEMIS solution is targeted at 100B+ global aquafeed market, which will allow the aquaculture industry to move to more sustainable grounds and help valorize substantial amounts of agricultural sidestreams, contributing to a circular economy.
The Venture Kick funds will be used to further advance bioprocessing and engineering solutions for KIDEMIS mycoprotein. kidemis.com
Orio Therapeutics: Redefining regeneration through protein engineering
Promising therapeutic proteins for tissue repair exist, yet their clinical translation is often poor due to inadequate delivery. The limited success of growth factors and other protein-based therapies is attributed to unadapted delivery methods. Administered molecules tend to disperse rapidly, demanding repeated high doses to maintain sufficient levels at the injection site. This excessive protein delivery strategy frequently leads to severe side effects.
Addressing this, Orio Therapeutics devised a versatile delivery system based on protein interactions. This system immobilizes proteins at the site of delivery, enhancing local therapeutic effects and minimizing systemic diffusion. This approach lowers drug usage, costs, and side effects while improving therapeutic outcomes. Orio Therapeutics' first application is a cardioprotective drug for post-heart attack care. Both EPFL alumni, Prof. Mikaël Martino and Dr. Ziad Julier developed the technology at Monash University's Australian Regenerative Medicine Institute and incorporated the company in Monthey in early 2023. Orio Therapeutics will keep operating in both Monthey and Melbourne to leverage the strategic advantages offered at both locations.
Funds from Venture Kick's stage 1 will bolster fundraising efforts and facilitate market validation.
Rheo: Stream vital patient data from anywhere
Hospitals are full of overworked nurses going bed-to-bed, manually taking vital signs multiple times per day for 1 billion inpatients annually. This is time-consuming, the quality is uneven, and it's not frequent enough for robust predictions.
Rheo’s vital+ solution replaces all manual patient vitals measurements in the hospital with a data stream from upper arm sensors.(USD 5B/year market). It seamlessly extends to patients' homes with cellular connectivity (USD 15B/year market). Additional predictive analytics enrich the data stream (USD 50B/year market).
Rheo’s founder CEO Dr. Philipp Vetter had previously built clinical data streams for millions of patients and worked with Boston-based co-founder CTO Jonathan Fisher to develop an FDA-registered medical device.
The Venture Kick funds will be used for hospital studies to establish product-market fit in the US.
Aquaculture (farmed seafood) is growing at substantial rates mainly due to ocean depletion and changes from meat to a more healthy diet, however, aquafeed supply is under pressure and is in search of sustainable solutions. On the other hand, there is a problem of proper utilization of agricultural sidestreams, which currently are accumulating in huge quantities or ending up in landfills. With KIDEMIS proprietary fermentation technology low-value sidestreams are converted to low-cost, sustainable & high-quality nutrition solutions, which could be used in either feed or food. In particular, KIDEMIS mycoprotein is set to disrupt aquafeed by providing economically viable, SDG-compliant, and nutritionally superior solutions for the industry.
The company was established in 2023. Founders and Board Members include CEO Dr Constantin Marakhov, CSO/CTO Sean Wassermann, and John Ericsson responsible for Finance/Strategy. KIDEMIS solution is targeted at 100B+ global aquafeed market, which will allow the aquaculture industry to move to more sustainable grounds and help valorize substantial amounts of agricultural sidestreams, contributing to a circular economy.
The Venture Kick funds will be used to further advance bioprocessing and engineering solutions for KIDEMIS mycoprotein. kidemis.com
Orio Therapeutics: Redefining regeneration through protein engineering
Promising therapeutic proteins for tissue repair exist, yet their clinical translation is often poor due to inadequate delivery. The limited success of growth factors and other protein-based therapies is attributed to unadapted delivery methods. Administered molecules tend to disperse rapidly, demanding repeated high doses to maintain sufficient levels at the injection site. This excessive protein delivery strategy frequently leads to severe side effects.
Addressing this, Orio Therapeutics devised a versatile delivery system based on protein interactions. This system immobilizes proteins at the site of delivery, enhancing local therapeutic effects and minimizing systemic diffusion. This approach lowers drug usage, costs, and side effects while improving therapeutic outcomes. Orio Therapeutics' first application is a cardioprotective drug for post-heart attack care. Both EPFL alumni, Prof. Mikaël Martino and Dr. Ziad Julier developed the technology at Monash University's Australian Regenerative Medicine Institute and incorporated the company in Monthey in early 2023. Orio Therapeutics will keep operating in both Monthey and Melbourne to leverage the strategic advantages offered at both locations.
Funds from Venture Kick's stage 1 will bolster fundraising efforts and facilitate market validation.
Rheo: Stream vital patient data from anywhere
Hospitals are full of overworked nurses going bed-to-bed, manually taking vital signs multiple times per day for 1 billion inpatients annually. This is time-consuming, the quality is uneven, and it's not frequent enough for robust predictions.
Rheo’s vital+ solution replaces all manual patient vitals measurements in the hospital with a data stream from upper arm sensors.(USD 5B/year market). It seamlessly extends to patients' homes with cellular connectivity (USD 15B/year market). Additional predictive analytics enrich the data stream (USD 50B/year market).
Rheo’s founder CEO Dr. Philipp Vetter had previously built clinical data streams for millions of patients and worked with Boston-based co-founder CTO Jonathan Fisher to develop an FDA-registered medical device.
The Venture Kick funds will be used for hospital studies to establish product-market fit in the US.